Lifeboat Foundation

“Now, nearly 2,000 people in and around Leticia are sick with COVID-19. About 70 have died. That might not sound like a colossal death toll at first. But because the surrounding state of Amazonas is sparsely populated, this amounts to the highest per-capita death rate in all of Colombia, according to figures from Colombia’s Health Ministry.”

The governor of Amazonas, Colombia, says it was impossible to cut the area off from Brazil, even as the virus spiked. Now the Colombian border town of Leticia is a coronavirus hot spot.

Continue reading “The Coronavirus Is Spreading Through Indigenous Communities In The Amazon” »

Speed as important as size in predicting potentially damaging impacts of coronal mass ejections.

Space weather forecasters need to predict the speed of solar eruptions, as much as their size, to protect satellites and the health of astronauts, scientists have found.

Continue reading “Scientists Find Speed Key to Protecting Astronauts and Satellites From Space Storms” »

Miniaturization has enabled technology like smartphones, health watches, medical probes and nano-satellites, all unthinkable a couple decades ago. Just imagine that in the course of 60 years, the transistor has shrunk from the size of your palm to 14 nanometers in dimension, 1000 times smaller than the diameter of a hair.

Miniaturization has pushed technology to a new era of optical circuitry. But in parallel, it has also triggered new challenges and obstacles, for example, controlling and guiding light at the nanometer scale. Researchers are looking for techniques to confine light into extremely tiny spaces, millions of times smaller than current ones. Studies had earlier found that metals can compress light below the wavelength-scale (diffraction limit).

In that aspect, graphene, a material composed from a single layer of carbon atoms, which exhibits exceptional optical and electrical properties, is capable of guiding light in the form of plasmons, which are oscillations of electrons that strongly interact with light. These graphene plasmons have a natural ability to confine light to very small spaces. However, until now, it was only possible to confine these plasmons in one direction, while the actual ability of light to interact with small particles like atoms and molecules resides in the volume into which it can be compressed. This type of confinement in all three dimensions is commonly regarded as an optical cavity.

Regeneron Pharmaceuticals announced Thursday that it’s started the first clinical trial of its experimental coronavirus antibody drug.

The antibody cocktail is being tested in four human populations. Two groups of people will receive the drug to test its effectiveness as a treatment for Covid-19; the other two will receive it as a possible prevention.

“We’ll be hopefully to quickly test the safety and then start understanding the efficacy for four major different settings of this virus challenge,” Regeneron’s chief scientific officer, Dr. George Yancopoulos, said on CNBC’s “Squawk Box.” Yancopoulos said he thinks that, “if all goes well,” the company could have “definitive data” within a few months on the effectiveness of the antibody cocktail.

Continue reading “Regeneron sees ‘a lot of reason for hope’ as human testing of its coronavirus drug begins” »

Recent therapeutic trials of “classical” psychedelic drugs, such as psilocybin (from magic mushrooms) or LSD, have reported benefits to wellbeing, depression and anxiety. These effects seem to be linked to a sense of “ego dissolution” — a dissolving of the subjective boundaries between the self and the wider world. However, the neurochemistry behind this effect has been unclear. Now a new paper, published in Neuropsychopharmacology, suggests that changes in brain levels of the neurotransmitter glutamate are key to understanding reports of ego dissolution — and perhaps the therapeutic effects of psychedelics.

Natasha Mason at Maastricht University, the Netherlands, and colleagues recruited 60 participants for their study. All had taken a psychedelic drug before, but not in the three months prior to the study. Half received a placebo and the other half were given a low to moderate dose of psilocybin (0.17 mg/kg of body weight).

The team then used a technique called proton magnetic resonance spectroscopy (MRS) to look at concentrations of glutamate (as well as other neurochemicals) in the medial prefrontal cortex (mPFC) and the hippocampus — two regions that have been implicated as key to the psychedelic drug experience. The team also looked at patterns of “functional connectivity” within networks of brain regions, a measure of how closely correlated brain activity is across those regions. Six hours after taking the drug or placebo, the participants reported on their subjective experiences using two surveys: The 5 Dimensions of Altered States of Consciousness and the Ego Dissolution Inventory.

Continue reading “Psilocybin Alters Brain Levels Of The Neurotransmitter Glutamate — And This Could Explain Why Users Experience ‘Ego Dissolution’” »

“ “The monitoring of human health and well-being with the use of wearables is considered critical in the next generation of biomedical devices,” write the authors. “[But] most existing paper-based devices are designed for one-time use only, functioning under relatively intense capillary flow into the paper, which ceases upon saturation… [Our approach] can function as a key part of a platform for long-term sweat sampling and biomarker monitoring.””

Researchers have designed a paper-based wearable device that can monitor your sweat for 10-days at a time to detect important information about your health.

WASHINGTON — SpaceX’s Crew Dragon spacecraft is performing well enough on orbit to give NASA confidence that the mission can last until August, an agency official said June 9.

Ken Bowersox, the acting associate administrator for human exploration and operations at NASA, told an online meeting of two National Academies committees that NASA had been monitoring the health of the Crew Dragon spacecraft since its launch May 30 on the Demo-2 mission, carrying NASA astronauts Bob Behnken and Doug Hurley to the International Space Station.

NASA, he noted, had not set a length for the mission, saying they wanted to see how the Dragon performed in space. “The Dragon is doing very well, so we think it’s reasonable for the crew to stay up there a month or two,” he told members of the Aeronautics and Space Engineering Board and Space Studies Board.